



APIC

Spreading knowledge.
Preventing infection.™



APIC

Association for Professionals in
Infection Control and Epidemiology

Voice for Infection Prevention Chapter Legislative Representatives Update

November 2016



APIC

Association for Professionals in
Infection Control and Epidemiology

Legislative Updates



Board of Directors' Voice for Infection Prevention Advocacy Day 2016



Federal Budget Status

Continuing Resolution passed – September 29, 2016

- Government funding continues at current level until Dec. 6, 2016
- Zika efforts received \$1.1 billion in funding

FY2017 Labor, HHS, Education Appropriations

- **NHSN** - House and Senate Appropriations Committees agree on \$21 million funding level. **APIC Supports**
- **Antibiotic Resistance Solutions Initiative** –
House Appropriations Committee proposal is \$160 million
Senate Appropriations Committee proposal is \$163 million.
APIC prefers the Senate proposal.

APIC Funding Priorities

Budget Item	2016 Funding	Administration Budget Request	House Markup	Senate Markup
Antibiotic Resistance Initiative - CDC	\$160,000,000	\$200,000,000	\$160,000,000	\$163,000,000
National Healthcare Safety Network- CDC	\$21,000,000	\$21,000,000	\$21,000,000	\$21,000,000
Advanced Molecular Detection - CDC	\$30,000,000	\$30,000,000	\$30,000,000	\$30,000,000
Emerging Infectious Diseases - CDC	\$147,000,000	\$147,000,000	\$125,000,000	\$147,000,000
EPI and Lab Capacity-PPHF	\$40,000,000	\$40,000,000	\$40,000,000	\$40,000,000
Healthcare Associated Infections - CDC/PPHF	\$12,000,000	\$12,000,000	\$12,000,000	\$12,000,000
HAI Research Activity - AHRQ	\$37,253,000	\$34,000,000	\$36,000,000	\$37,253,000

VIP Advocacy Competition - Update

In May, APIC kicked off it's annual Voice for Infection Prevention (VIP) Advocacy Challenge. This competition aims to see which state can get the highest percent of APIC members to contact their Members of Congress about NHSN and Antibiotic Resistance Solutions Initiative funding.

VIP Leader Board

State	% Participation
Maine	67%
District of Columbia	27%
Arizona	21%
Rhode Island	19%
Delaware	19%



Use this link to send a letter: <http://cqrcengage.com/apic/app/write-a-letter?0&engagementId=211313>

APIC has joined allied organizations in supporting:

- Federal funding increases for antibiotic resistance programs in the CDC, NIH, and AHRQ;
- Urging passage of S. 185, the PATH Act, which would establish a new limited population antibacterial drug approval pathway;
- Supporting \$1.1 billion in funding to combat Zika in the September Continuing Resolution;



The Campaign to End Antibiotic Overuse



APIC

Association for Professionals in
Infection Control and Epidemiology

Regulatory Updates

APIC comments submitted since our Annual Conference meeting:

- **CMS** – [Hospital Inpatient Prospective Payment System](#)
- **CMS** – [Inpatient Rehabilitation Facility PPS](#)
- **CMS** -- [Skilled Nursing Facility PPS](#)
- **CMS** – [Merit-Based Incentive Payment System \(MIPS\)](#)
- **CMS** – [Update to Hospital/CAH CoPs](#)
- **CMS** – [End-Stage Renal Disease PPS](#)
- **CMS** – [Home Health PPS](#)
- **CMS** – [Hospital Outpatient/ASC PPS](#)
- **HHS/CDC** – [Update of Quarantine Regulations for Control of Communicable Diseases](#)



Comments in process:

- **FDA** – Safety and efficacy of consumer antiseptics
- **FDA** – Coordinated development of antimicrobial drugs and susceptibility test devices





Other infection-related issues being discussed by federal agencies:

- Contaminated heater-cooler devices (CDC and FDA)
- Zika guidance (CDC and FDA)
- New 2020 targets for the National Action Plan to Prevent HAIs (HHS)
- Reprocessing medical devices (CDC and FDA)



Care Setting	Last Action	Release Status
Hospital/Critical Access Hospital	<u>APIC comments 8/15/16</u>	Unknown
Long-Term Care	<u>APIC comments 9/10/15</u>	<u>Final Rule: 10/4/16</u>
Home Health Agencies	<u>APIC comments 11/25/14</u>	Unknown
End-Stage Renal Disease	<u>APIC comments made prior to release of the draft rule 4/1/15</u>	Not yet proposed

Updates from the July 2016 HICPAC Meeting

These slides are not an official record of the HICPAC meeting. Slide content developed based on CDC content, APIC staff notes, and APIC CDC liaison notes.

New Epicenters created in 11 locations with Major Areas of Investigation:

- Determinants of Pathogen Transmission in Healthcare Setting
- PPE Effectiveness Both “Standard” PPE and “High Level” PPE (e.g. PPE used for Ebola patients)
- Self contamination during doffing
- Human factors engineering principles
- Environmental Factors in Transmission
- Source Control



FY 2016 Broad Research Priorities (BAA)

- Microbiome assessment and intervention to address antibiotic resistance
- Understanding and prevention of antibiotic-resistant organism transmission and emergence
- Enhanced understanding of medication safety threats
- Evaluation of the capacity for tracking and preventing antibiotic-resistance threats in non-acute care settings

Areas of opportunity:

- Better lab capacity for accurate differential diagnosis of virus vs. bacterial infection
- Innovations in testing and monitoring of microbiota

Current Update:

Targeted focus on: UTIs and Pneumonia, Vancomycin and quinolones

Standards update

- The Joint Commission standard to go into effect early 2017
- Anthem and BC/BS adding compliance with CDC core elements to their “quality insights hospital incentive” programs

Areas of opportunity:

- Determining and defining “inappropriate use”
- Continuing innovations in managing and decreasing device use



November 14-20, 2016 “Get Smart About Antibiotics” Week



Candida Auris

- New candida species, first reported 2009 in Japan, later 2011 in South Korea, India, Pakistan and 2015 in UK
 - Can cause invasive infections, predominantly fungemia
 - Highly resistant to all classes of antifungal treatments
 - Mortality about 60%
 - requires molecular testing to type it
 - hard to detect using standard testing methods
 - can be misidentified when using biochemical methods
 - CDC working with EPA and FDA to understand disinfection
-
- **Areas of opportunity:**
 - Understanding how long it lives in environment
 - Learning how and why it withstands desiccation
 - Creating lab capacity and tools to accurately identify candida auris





Plasmid-mediated colistin resistance (mcr-1 gene)

CDC working with DoD and state and local health departments

- Found globally
 - food animals
 - environment
 - ill patients
 - asymptomatic colonized individuals

- Case reported November 2015
- Had been undetected since the 1980s
- A real time PCR assay developed to detect mcr-1 gene

Area of opportunity:

- Improving detection and increasing support for front line microbiology labs



Thank You

Questions?

**For Government Affairs Questions:
legislation@apic.org**

**For Practice Guidance Questions:
practice@apic.org**



APIC

Spreading knowledge.
Preventing infection.™